T time: Emerging and new therapies for peripheral T-cell lymphoma

Alain Mina*, Barbara Pro

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Peripheral T-cell Lymphomas (PTCL) are a heterogenous group of aggressive non-Hodgkin lymphomas that are far less sensitive to chemotherapy than their B-cell counterparts. Despite their poor prognosis, they are treated similarly to most aggressive B-cell lymphomas, heavily relying on CHOP or CHOP-like combination chemotherapy irrespective of their different subtypes or biology. The last decade has seen the emergence of many targeted therapies that include histone deacetylase inhibitors, hypomethylating agents, monoclonal antibodies and PIK3 inhibitors, among others. However, prognosis remains poor especially in the relapsed/refractory setting. Using an extensive pubmed search, the authors will be summarizing the different trials that led to these approved targeted agents as well as novel combination strategies. The fundamental recognition that different subtypes of PTCL have specific biological features that drive not only proliferation, but also responses to different treatment approaches, should be informing the design of future clinical trials.

Original languageEnglish (US)
Article number100889
JournalBlood Reviews
DOIs
StateAccepted/In press - 2021

Keywords

  • Histone deacetylase inhibitors
  • Hypomethylating agents
  • Immunotherapy
  • Lymphoma
  • Monoclonal antibodies
  • Peripheral T-cell lymphomas
  • Pralatrexate

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'T time: Emerging and new therapies for peripheral T-cell lymphoma'. Together they form a unique fingerprint.

Cite this